Barry P Flannelly Incyte Corp (INCY) insider trading activity

Barry P Flannelly is EVP & General Manager US of INCYTE CORP. Currently has a direct ownership of 58,042 shares of INCY, which is worth approximately $4.42 Million. The most recent transaction as insider was on Jul 16, 2024, when has been sold 1,306 shares (Common Stock) at a price of $64.19 per share, resulting in proceeds of $83,832. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 58K

0% 3M change

28.68% 12M change

Total Value Held $4.42 Million

Barry P Flannelly Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 16 2024	SELL Open market or private sale	$83,832 $64.19 p/Share	1,306 Reduced 2.2%	58,042 Common Stock
Jul 15 2024	SELL Payment of exercise price or tax liability	$71,381 $64.25 p/Share	1,111 Reduced 1.84%	59,348 Common Stock
Jul 15 2024	BUY Grant, award, or other acquisition	-	9,925 Added 14.1%	60,459 Common Stock
Jul 09 2024	SELL Open market or private sale	$488,880 $60.0 p/Share	8,148 Reduced 13.89%	50,534 Common Stock
Jul 02 2024	SELL Payment of exercise price or tax liability	$454,158 $59.02 p/Share	7,695 Reduced 11.59%	58,682 Common Stock
Jun 12 2024	SELL Open market or private sale	$1,149,840 $60.0 p/Share	19,164 Reduced 22.4%	66,377 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	7,377 Added 7.98%	85,080 Common Stock
Jan 17 2024	SELL Payment of exercise price or tax liability	$225,939 $61.48 p/Share	3,675 Reduced 4.52%	77,703 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	9,668 Added 10.62%	81,378 Common Stock
Jul 03 2023	SELL Payment of exercise price or tax liability	$391,352 $62.08 p/Share	6,304 Reduced 8.08%	71,710 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	4,980 Added 6.03%	77,654 Common Stock
Jul 07 2022	SELL Open market or private sale	$228,059 $79.38 p/Share	2,873 Reduced 3.8%	72,674 Common Stock
Jul 05 2022	SELL Payment of exercise price or tax liability	$277,850 $79.25 p/Share	3,506 Reduced 4.43%	75,547 Common Stock
Jul 02 2022	BUY Grant, award, or other acquisition	-	13,529 Added 14.61%	79,053 Common Stock
Apr 08 2022	SELL Open market or private sale	$3,661,538 $83.23 p/Share	43,993 Reduced 40.3%	65,163 Common Stock
Apr 08 2022	BUY Exercise of conversion of derivative security	$2,949,319 $70.45 p/Share	41,864 Added 32.08%	88,640 Common Stock
Jan 01 2022	BUY Grant, award, or other acquisition	-	8,678 Added 11.42%	67,292 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	2,734 Added 4.46%	58,614 Common Stock
Jul 06 2021	SELL Payment of exercise price or tax liability	$22,752 $83.34 p/Share	273 Reduced 0.49%	55,880 Common Stock
Jul 02 2021	SELL Payment of exercise price or tax liability	$166,324 $83.58 p/Share	1,990 Reduced 3.42%	56,153 Common Stock
Jul 02 2021	BUY Grant, award, or other acquisition	-	7,853 Added 11.9%	58,143 Common Stock
Jan 25 2021	SELL Open market or private sale	$274,400 $100.0 p/Share	2,744 Reduced 5.2%	49,994 Common Stock
Jan 15 2021	BUY Grant, award, or other acquisition	-	11,522 Added 17.93%	52,738 Common Stock
Nov 16 2020	BUY Grant, award, or other acquisition	-	1,232 Added 2.9%	41,216 Common Stock
Nov 02 2020	SELL Open market or private sale	$1,732,000 $86.6 p/Share	20,000 Reduced 33.34%	39,984 Common Stock

Also insider at

TARA

Protara Therapeutics, Inc. Healthcare

BPF